Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment

Blood (2015) 126 (23): 2891.

https://doi.org/10.1182/blood.V126.23.2891.2891

Published: 2015

Journal Articles

Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial

Blood (2014) 124 (21): 1920.

https://doi.org/10.1182/blood.V124.21.1920.1920

Published: 2014

Journal Articles

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

Blood (2013) 122 (21): 2759.

https://doi.org/10.1182/blood.V122.21.2759.2759

Published: 2013

Journal Articles

Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups

Mark Reinwald, MD, Daniel Nowak, MD, Uwe Platzbecker, MD, Aristoteles Giagounidis, MD, Katharina S. Götze, Oliver G. Ottmann, MD, Detlef Haase, Katayoon Shirneshan, Richard F Schlenk, MD, Anne Letsch, MD, Michael Lübbert, MD, Arnold Ganser, Verena Nowak, Stephanie Fey, Julia Obländer, Maximilian Mossner, Ulrich Germing, Wolf-Karsten Hofmann, MD, Florian Nolte, MD

Blood (2012) 120 (21): 3801.

https://doi.org/10.1182/blood.V120.21.3801.3801

Published: 2012

Journal Articles

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Ulrich Keilholz, Anne Letsch, Antonia Busse, Anne Marie Asemissen, Sandra Bauer, Igor Wolfgang Blau, Wolf-Karsten Hofmann, Lutz Uharek, Eckhard Thiel, Carmen Scheibenbogen

Blood (2009) 113 (26): 6541–6548.

https://doi.org/10.1182/blood-2009-02-202598

Published: 2009

Journal Articles

Human Bone Marrow as a Source of Multifunctional CMV-Specific CD4+ T Cells for Adoptive Cell Therapy.

Il-Kang Na, MD, Anne Letsch, M.D., Ines Noack, Sandra Bauer, Jens Geginat, Petra Reinke, M.D., Hans Dieter Volk, M.D., Eckhard Thiel, M.D., Carmen Scheibenbogen, M.D.

Blood (2007) 110 (11): 2973.

https://doi.org/10.1182/blood.V110.11.2973.2973

Published: 2007

Journal Articles

Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.

Ulrich Keilholz, MD, Anne Letsch, MD, Antonia Busse, MD, Annemarie Asemissen, MD, Igor W. Blau, MD, Wolf K. Hofmann, MD, Lutz Uharek, MD, Eckhard Thiel, MD, Carmen Scheibenbogen, MD

Blood (2007) 110 (11): 902.

https://doi.org/10.1182/blood.V110.11.902.902

Published: 2007

Journal Articles

Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial.

Ulrich Keilholz, MD, Anne Letsch, Antonia Busse, Anne M. Asemissen, Alexander Schmittel, Wolf K. Hofmann, Lutz Uharek, Igor W. Blau, Eckhard Thiel, Carmen Scheibenbogen

Blood (2006) 108 (11): 567.

https://doi.org/10.1182/blood.V108.11.567.567

Published: 2006

Journal Articles

Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation.

Chiara Gentilini, MD, Anne Letsch, MD, Annemarie Asemissen, MD, Arne Muessig, MD, Katrin Rieger, MD, Carmen Scheibenbogen, Eckhard Thiel, Lutz Uharek

Blood (2006) 108 (11): 3683.

https://doi.org/10.1182/blood.V108.11.3683.3683

Published: 2006

Journal Articles

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

Robert Godal, Ulrich Keilholz, Lutz Uharek, Anne Letsch, Anne Marie Asemissen, Antonia Busse, Il-Kang Na, Eckhard Thiel, Carmen Scheibenbogen

Blood (2006) 107 (8): 3205–3211.

https://doi.org/10.1182/blood-2005-07-2880

Published: 2006

Journal Articles

WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia.

Keilholz Ulrich, MD, Carmen Scheibenbogen, MD, Anne Letsch, MD, Anne Marie Asemissen, MD, Wolf Karsten Hofmann, MD, Lutz Uharek, MD, Blau Wolfgang, MD, Thiel Eckhard, MD

Blood (2005) 106 (11): 406.

https://doi.org/10.1182/blood.V106.11.406.406

Published: 2005

Journal Articles

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

Carmen Scheibenbogen, Anne Letsch, Eckhard Thiel, Alexander Schmittel, Volker Mailaender, Steffi Baerwolf, Dirk Nagorsen, Ulrich Keilholz

Blood (2002) 100 (6): 2132–2137.

https://doi.org/10.1182/blood-2002-01-0163

Published: 2002

NARROW

Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment

Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Human Bone Marrow as a Source of Multifunctional CMV-Specific CD4+ T Cells for Adoptive Cell Therapy.

Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.

Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial.

Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation.

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia.

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only